Guardant Health Target of Unusually Large Options Trading (NASDAQ:GH)

Guardant Health, Inc. (NASDAQ:GH) was the target of unusually large options trading on Friday. Investors purchased 4,097 call options on the stock. This represents an increase of 78% compared to the average daily volume of 2,301 call options.

Wall Street Analyst Weigh In

GH has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their price target on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Raymond James reaffirmed an “outperform” rating and issued a $59.00 price target (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Morgan Stanley raised their price target on Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. Canaccord Genuity Group raised their price target on Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Finally, Piper Sandler lifted their target price on Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Twenty analysts have rated the stock with a buy rating, Based on data from MarketBeat, Guardant Health currently has a consensus rating of “Buy” and an average target price of $48.40.

Institutional Trading of Guardant Health

Institutional investors have recently bought and sold shares of the business. Polar Asset Management Partners Inc. grew its holdings in shares of Guardant Health by 1,902.2% in the 4th quarter. Polar Asset Management Partners Inc. now owns 454,500 shares of the company’s stock valued at $13,885,000 after buying an additional 431,800 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Guardant Health in the 4th quarter valued at $79,000. Twinbeech Capital LP acquired a new position in shares of Guardant Health in the 4th quarter valued at $367,000. Two Sigma Advisers LP grew its holdings in shares of Guardant Health by 96.7% in the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock valued at $70,742,000 after buying an additional 1,138,300 shares during the period. Finally, Two Sigma Investments LP grew its holdings in shares of Guardant Health by 38.5% in the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company’s stock valued at $57,761,000 after buying an additional 525,368 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $42.89 on Friday. The firm has a market cap of $5.29 billion, a P/E ratio of -12.05 and a beta of 1.50. The firm has a 50 day simple moving average of $42.83 and a 200 day simple moving average of $32.74. Guardant Health has a fifty-two week low of $15.81 and a fifty-two week high of $50.89.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. On average, sell-side analysts expect that Guardant Health will post -2.9 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.